About Us
Mission
Our mission is to transform CNS drug discovery by uniting AI-powered drug discovery with deep clinical expertise, thereby advancing therapies that make a real and lasting difference for patients and their loved ones.
Vision
Our vision is to lead the future of CNS therapeutics by pairing advanced technology with human-centered science, delivering treatments that bring real hope and measurable impact to those living with rare CNS disorders.
Supporting Pillars
High Clinical-Predictive AI Platform
We have a track record of clinical success, enabling the identification of compounds with high likelihood of clinical efficacy.
Operational Excellence
We have successfully advanced treatments that address unmet needs in CNS rare diseases.
Patient-Centered Research
Our work is guided by understanding and incorporating the real experiences of patients and their families.
Global Collaboration
We partner with leading research institutions across Europe and North America.
Leadership Team
Silvia Panigone, Ph.D, MBA
CEO and Board Member
Rossella Medori, M.D
Chief Medical Officer
Kevin McAllister, Ph.D, MBA
Chief Scientific Officer
Oscar Huertas, M.Sc
Chief Technology Officer
Board of Directors
Silvia Panigone, Ph.D, MBA
CEO and Board Member
Ed Torres, B.A., MBA
Board Member
Wendy Johnson, M.S., MBA
Board Member
Néstor Oller, MBA
Board Member
Stanislaw Knaflewski, MBA
Board Member
Scientific Advisory Board
